RBC Capital Lowers Illumina's Price Target to $247, Maintains Outperform Rating
Feb 10, 2025 16:52
CST Updated
16:52
Illumina
Diagnostic Product Developer
Gelonghui February 10 | RBC Capital: Downgraded Illumina's target price from $250 to $247, maintaining an "Outperform" rating. (Gelonghui)